US Stock Market Move | AI will be used to develop weight loss drugs, and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has increased by nearly 2% against the trend.
On Friday, Novo Nordisk (NVO.US) defied the trend and rose nearly 2%, closing at $86.77.
On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose nearly 2% against the market trend, closing at $86.77 USD. In terms of news, the company and the U.S. technology company Valo Health recently announced their agreement to expand the scope of their collaboration to develop up to 11 drugs by 2023, utilizing human data and artificial intelligence (AI) to develop up to 20 new therapies for obesity, type 2 diabetes, and cardiovascular diseases.
Related Articles
SINOHYTEC (02402) completed the placement of a total of 8.88 million shares, raising a net amount of HK$198 million.
TSUGAMI CHINA (01651) spent 4.2252 million Hong Kong dollars to repurchase 130,000 shares on December 23rd.
Deputy General Manager Yu Min and core technical personnel Fang Chuan resign from SinoHytec (02402).
SINOHYTEC (02402) completed the placement of a total of 8.88 million shares, raising a net amount of HK$198 million.
TSUGAMI CHINA (01651) spent 4.2252 million Hong Kong dollars to repurchase 130,000 shares on December 23rd.
Deputy General Manager Yu Min and core technical personnel Fang Chuan resign from SinoHytec (02402).
RECOMMEND
